Adoptive Transfer of siRNA Cblb-Silenced CD8+ T Lymphocytes Augments Tumor Vaccine Efficacy in a B16 Melanoma Model
Open accessThe DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Abstract
The ubiquitin ligase Cbl-b is an established regulator of T cell immune response thresholds. We recently showed that adoptive cell transfer (ACT) of cblb(-/-) CD8(+) T cells enhances dendritic cell (DC) immunization-mediated anti-tumor effects in immune-competent recipients. However, translation of cblb targeting to clinically applicable concepts requires that inhibition of cblb activity be transient and reversible. Here we provide experimental evidence that inhibition of cblb using chemically synthesized siRNA has such potential. Silencing cblb expression by ex vivo siRNA transfection of polyclonal CD8(+) T cells prior to ACT increased T cell tumor infiltration, significantly delayed tumor outgrowth, and increased survival rates of tumor-bearing mice. As shown by ex vivo recall assays, cblb silencing resulted in significant augmentation of intratumoral T cell cytokine response. ACT of cblb-silenced polyclonal CD8(+) T cells combined with DC-based tumor vaccines predominantly mediated anti-tumor immune responses, whereas no signs of autoimmunity could be detected. Importantly, CBLB silencing in human CD8(+) T cells mirrored the effects observed for cblb-silenced and cblb-deficient murine T cells. Our data validate the concept of enhanced anti-tumor immunity by repetitive ACT of ex vivo cblb siRNA-silenced hyper-reactive CD8(+) T cells as add-on adjuvant therapy to augment the efficacy of existing cancer immunotherapy regimens in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among these, CBLB has been best studied as an intracellular immune checkpoint that can be targeted in T cells to improve tumor control in mouse models (Chiang et al., 2007; Hinterleitner et al., 2012).”
From Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function (2018) · cites this paper as Hinterleitner et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 1×
“Accordingly, Sipuleucel-T (Provenge), a dendritic cell (DC) vaccine loaded with an antigen/GM-CSF conjugate, is the first active immunization approach approved for treatment of hormone-refractory prostate cancer [1,2].”
BackgroundLMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587 · cited 1×
“by inappropriate insertion of T cell receptor (TCR)-transgenic lentiviral vectors within proto-oncogenes [9], potentially causing T cell leukemogenesis.”
BackgroundCancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603 · cited 1×
“Alternatively, T cells transduced with tumor antigen-specific T cell receptor (TCR) transgenes have been used to treat patients with melanoma [5,6] or B cell lymphoma [7], thereby bypassing the need to expand tumor-specific T cells ex vivo.”
BackgroundAdoptive cell transfer: a clinical path to effective cancer immunotherapy
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A., & Dudley, M. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2355 · Cited by 1,659 · cited 1×
“As an example, ACT using ex vivo expanded T cells can induce tumor regression in patients with advanced melanoma [3,4].”
MethodSavoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012 · cited 1×
“However, this approach also causes immune-related toxicity [30,31].”
BackgroundLugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966 · cited 1×
“Cell Lines and Tumor Model 1610(5) B16ova cells [34] (provided by Drs.”
BackgroundT-cell regulation by CD28 and CTLA-4
Alegre, M.-L., Frauwirth, K. A., & Thompson, C. B. (2001) · Nature Reviews Immunology · doi:10.1038/35105024 · Cited by 914 · cited 1×
“during T cell activation [28].”
Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b
Bachmaier, K., Krawczyk, C., Kozieradzki, I., Kong, Y.-Y., Sasaki, T., Oliveira-dos-Santos, A., Mariathasan, S., Bouchard, D., Wakeham, A., Itie, A., et al. (2000) · Nature · doi:10.1038/35003228 · Cited by 666 · cited 2×
“Specifically, Cbl-b regulates adaptive immunity by setting activation thresholds of mature lymphocytes [11,12,13].”
BackgroundSelf-citationCbl: many adaptations to regulate protein tyrosine kinases
Thien, C. B. F., & Langdon, W. Y. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35067100 · Cited by 625 · cited 1×
“Cbl family members have evolutionarily conserved roles in regulating protein tyrosine kinases [10].”
Background
Cited by
Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function
Shifrut, E., Carnevale, J., Tobin, V., Roth, T. L., Woo, J. M., Bui, C. T., Li, P. J., Diolaiti, M. E., Ashworth, A., & Marson, A. (2018) · Cell · doi:10.1016/j.cell.2018.10.024 · Cited by 573
Shah, N. N., Qin, H., Yates, B., Su, L., Shalabi, H., Raffeld, M., Ahlman, M. A., Stetler-Stevenson, M., Yuan, C., Guo, S., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000219 · Cited by 165
The expanding role for small molecules in immuno-oncology
Offringa, R., Kötzner, L., Huck, B. R., & Urbahns, K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00538-9 · Cited by 150
E3 ubiquitin ligase Cbl-b in innate and adaptive immunity
Qingjun, L., Zhou, H., Langdon, W. Y., & Zhang, J. (2014) · Cell Cycle · doi:10.4161/cc.29213 · Cited by 121
“Indeed, transfer of siRNA Cbl-bsilenced CD8 T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model.(114,115) Thus, abrogating Cbl-b expression in effector T cells may improve the efficacy of adoptive therapy of some human malignancies.”
BackgroundModulation of Immune Cell Functions by the E3 Ligase Cbl-b
Lutz‐Nicoladoni, C., Wolf, D. G. F., & Sopper, S. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00058 · Cited by 104
“Since cblb-deficient mice are largely protected from tumor formation (72, 73) and adoptive transfer of cblb negative or transiently silenced CD8 T cells in combination with DC vaccination delays tumor growth in several mouse models (74, 122) it was interesting to know whether loss of Cbl-b in DCs also contributes to t…”
BackgroundSelf-citationTargeting Cbl-b in cancer immunotherapy
Augustin, R. C., Bao, R., & Luke, J. J. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006007 · Cited by 101
Adoptive T-cell therapy for cancer: the era of engineered T cells
Bonini, C., & Mondino, A. (2015) · European Journal of Immunology · doi:10.1002/eji.201545552 · Cited by 93
Comparing photoporation and nucleofection for delivery of small interfering RNA to cytotoxic T cells
Wayteck, L., Xiong, R., Braeckmans, K., Smedt, S. C. D., & Raemdonck, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.002 · Cited by 83
“increase the tumor infiltration, T cell proliferation, and release of immune-stimulating cytokines [12,13].”
BackgroundChen, J., Zhu, H., Xia, J., Zhu, Y., Chen, X., Hu, Z., Yang, J., Wang, J., He, Y., Dai, J., et al. (2023) · Advanced Science · doi:10.1002/advs.202206306 · Cited by 81
Reprogramming the tumor microenvironment to enhance adoptive cellular therapy
Beavis, P. A., Slaney, C. Y., Kershaw, M. H., Gyorki, D. E., Neeson, P. J., & Darcy, P. K. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.11.003 · Cited by 81
IFT20 modulates ciliary PDGFRα signaling by regulating the stability of Cbl E3 ubiquitin ligases
Schmid, F. M., Schou, K. B., Vilhelm, M. J., Holm, M. S., Breslin, L., Farinelli, P., Larsen, L. A., Andersen, J. S., Pedersen, L. B., & Christensen, S. T. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201611050 · Cited by 67
Nurieva, R., Wang, J., & Sahoo, A. (2013) · Immunotherapy · doi:10.2217/imt.13.33 · Cited by 68
Gene Silencing via PDA/ERK2‐siRNA‐Mediated Electrospun Fibers for Peritendinous Antiadhesion
Liu, S., Wu, F., Gu, S., Wu, T., Chen, S., Chen, S., Wang, C., Huang, G., Jin, T., Cui, W., et al. (2018) · Advanced Science · doi:10.1002/advs.201801217 · Cited by 62
Freeley, M., & Long, A. (2013) · Biochemical Journal · doi:10.1042/bj20130950 · Cited by 59
Gavali, S., Liu, J., Li, X., & Paolino, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910800 · Cited by 59
Voisinne, G., García‐Blesa, A., Chaoui, K., Fiore, F., Bergot, E., Girard, L., Malissen, M., Burlet‐Schiltz, O., Gonzalez de Peredo, A., Malissen, B., et al. (2016) · Molecular Systems Biology · doi:10.15252/msb.20166837 · Cited by 50
“CBLB-deficient T cells have increased anti-tumor efficacy, suggesting that CBLB might be exploited as a drug target for the purpose of boosting T-cell responses against tumors (Hinterleitner et al , 2012).”
Cbl-b Deficiency Mediates Resistance to Programed Death-Ligand 1/Programed Death-1 Regulation
Fujiwara, M., Anstadt, E. J., & Clark, R. B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00042 · Cited by 42
“Moreover, we and others have shown that Cbl-b−/− T cells are resistant to suppression by Tregs (7–9) and TGF-β (7, 10, 11).”
BackgroundResultInfluentialReleasing the Immune System Brakes Using siRNAs Enhances Cancer Immunotherapy
Sioud, M. (2019) · Cancers · doi:10.3390/cancers11020176 · Cited by 40
“In this respect, silencing of Cbl-b expression in primary murine CD8+ T cells with siRNAs via nucleofection, followed by adoptive transfer of the cells into recipient mice enhanced the effects of an anti-cancer vaccine [126].”
BackgroundJafari, D., Mousavi, M. J., Shahbaz, S. K., Jafarzadeh, L., Tahmasebi, S., Spoor, J. K. H., & Esmaeilzadeh, A. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13560 · Cited by 39
Non-viral siRNA delivery to T cells: Challenges and opportunities in cancer immunotherapy
Hoeck, J. V., Braeckmans, K., Smedt, S. C. D., & Raemdonck, K. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121510 · Cited by 37
Rational combination immunotherapeutic approaches for effective cancer treatment
Phung, C. D., Nguyen, H. T., Tran, T. H., Choi, H., Yong, C. S., & Kim, J. O. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.020 · Cited by 36
Engineering lymphocytes with RNAi
Ramishetti, S., & Peer, D. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.12.002 · Cited by 34
Polymer-Based Constructs for Flexor Tendon Repair: A Review
Brebels, J., & Mignon, A. (2022) · Polymers · doi:10.3390/polym14050867 · Cited by 28
“Unfortunately, a bottleneck has gradually emerged in the siRNA technology around the transient silencing effect [208].”
BackgroundImmunobiology of chimeric antigen receptor T cells and novel designs
Walsh, Z. H., Yang, Y., & Kohler, M. E. (2019) · Immunological Reviews · doi:10.1111/imr.12794 · Cited by 28
Cblb -deficient T cells are less susceptible to PD-L1-mediated inhibition
Peer, S., Baier, G., & Gruber, T. (2017) · Oncotarget · doi:10.18632/oncotarget.18360 · Cited by 27
Self-citationEtxeberría, I., Olivera, I., Bolaños, E., Cirella, A., Teijeira, Á., Berraondo, P., & Melero, I. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0464-1 · Cited by 26
Zhang, L., Wang, S., Liu, Z., Zhang, L., Wang, S., & Wang, B. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.04.007 · Cited by 25
Biomaterials for polynucleotide delivery to anchorage-independent cells
Ansari, A. S., Santerre, P., & Uludağ, H. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb01833a · Cited by 25
Zhou, L., Yang, J., Zhang, K., Wang, T., Jiang, S., & Zhang, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01361 · Cited by 24
Immune modulation by genetic modification of dendritic cells with lentiviral vectors
Liechtenstein, T., Pérez‐Janices, N., Bricogne, C., Lanna, A., Dufait, I., Goyvaerts, C., Laranga, R., Padella, A., Vargas, F. A., Baratchian, M., et al. (2013) · Virus Research · doi:10.1016/j.virusres.2013.05.007 · Cited by 24
Engineering better immunotherapies via RNA interference
Sioud, M. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29754 · Cited by 24
“Interestingly, silencing of Cbl-b gene expression in primary murine CD8C T cells with siRNAs via nucleofection, followed by adoptive transfer of the cells into recipient mice potentiated the effects of a cancer vaccine in B16 melanoma model.(67) Gene silencing increased effector functions and infiltration rates of ado…”
BackgroundThe role of CBL family ubiquitin ligases in cancer progression and therapeutic strategies
Ren, J., Lv, L., Tao, X., Zhai, X., Chen, X., Yu, H., Zhao, X., Kong, X., Yu, Z., Dong, D., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1432545 · Cited by 23
Glycogen Synthase Kinase-3 Modulates Cbl-b and Constrains T Cell Activation
Tran, C. W., Saibil, S. D., Bihan, T. L., Hamilton, S. R., Lang, K. S., You, H., Lin, A. E., Garza, K. M., Elford, A. R., Tai, K., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1600396 · Cited by 20
“Loss of a single copy of Cblb has been shown to enhance antitumor T cell activity in murine models (36, 37), and inhibiting CBLB expression has also been demonstrated to increase effector function of human CD8 T cells in vitro (37).”
BackgroundSelf-citationEnhancing the Efficacy of Adoptive Cellular Therapy By Targeting Tumor-InDuced Immunosuppression
Beavis, P. A., Slaney, C. Y., Kershaw, M. H., Neeson, P. J., & Darcy, P. K. (2015) · Immunotherapy · doi:10.2217/imt.15.16 · Cited by 18
Goetz, B. T., An, W., Mohapatra, B. C., Zutshi, N., Iseka, F., Storck, M. D., Meza, J. L., Sheinin, Y. M., Band, V., & Band, H. (2016) · Oncotarget · doi:10.18632/oncotarget.9812 · Cited by 16
“Previous models have failed to accurately elucidate the role that CBL proteins play in a T-cell-specific manner as these models utilized a CBL-B null background [13, 14], which leads to the altered and/or enhanced function of B cells [19], macrophages [20, 21], mast cells [22], neutrophils [23, 24], and NKT-cells [25].”
BackgroundResultCbl‐family proteins as regulators of cytoskeleton‐dependent phenomena
Lee, H., & Tsygankov, A. Y. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24412 · Cited by 14
“Similarly, RNAi silencing of Cbl-b in T cells augments their responsiveness and antitumor activity (Hinterleitner et al., 2012).”
BackgroundPrecision Tools in Immuno-Oncology: Synthetic Gene Circuits for Cancer Immunotherapy
Bonfá, G., Blazquez-Roman, J. L., Tarnai, R., & Siciliano, V. (2020) · Vaccines · doi:10.3390/vaccines8040732 · Cited by 14
E3 Ubiquitin Ligases as Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease
Poels, K., Vos, W. G., Lutgens, E., & Seijkens, T. T. P. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00106 · Cited by 13
Hu, K., Yin, E. T. S., Hu, Y., & Huang, H. (2021) · Current Medical Science · doi:10.1007/s11596-021-2391-5 · Cited by 13
Gene editing: Towards the third generation of adoptive T-cell transfer therapies
Puig-Saus, C., & Ribas, A. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.06.001 · Cited by 12
Freeley, M., & Long, A. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.08.005 · Cited by 12
Immune Regulation by Ubiquitin Tagging as Checkpoint Code
Zeng, P., Ma, J., Yang, R., & Liu, Y. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_64 · Cited by 7
Manipulating the TCR signaling network for cellular immunotherapy: Challenges & opportunities
Matson, C. A., & Singh, N. J. (2020) · Molecular Immunology · doi:10.1016/j.molimm.2020.04.007 · Cited by 7
“Interestingly, a siRNA delivered to CD8 T cells to silence the expression of cbl-b showed improved tumor clearance (Hinterleitner et al., 2012) demonstrating that there is a potential therapeutic efficacy for modulating these pathways; particularly in the case of genetically modified T cells like CARs where these coul…”
BackgroundEngineering effective T-cell based antitumor immunity
Gruber, T., Hinterleitner, R., Pfeifhofer‐Obermair, C., Wolf, D. G. F., & Baier, G. (2013) · OncoImmunology · doi:10.4161/onci.22893 · Cited by 6
“We have recently demonstrated that an ex vivo synthetic small-interfering RNA (siRNA)-based approach that depletes casitas B-lineage lymphoma proto-oncogene b (CBLB) constitutes a rational strategy to achieve such goals, as it profoundly improves the efficacy of ACT for cancer immunotherapy.(1)”
BackgroundSelf-citationEngineering cell-based therapies
Blazquez-Roman, J. L., Pisani, M., & Siciliano, V. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824469-2.00023-3 · Cited by 5
Nath, P. R., & Isakov, N. (2024) · Life · doi:10.3390/life14121592 · Cited by 4
“…method to transfect Cbl-b-specific siRNA into T cells and combines it with adoptive T cell therapy. siRNA-transfected CD8+ T cells together with a DC-based tumor vaccine showed enhanced intratumoral inflammatory cytokine signaling and an augmented B16 melanoma inhibition in a murine model [39].”
Unleashing the Therapeutic Potential of Dendritic and T Cell Therapies Using RNA Interference
Sioud, M. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0290-4_15 · Cited by 3
siRNA Therapeutics to Treat Liver Disorders
Lai, C.-J., Martín-Higueras, C., & SALIDO, E. C. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_8 · Cited by 3
Melanoma Immunotherapy: Overcoming Obstacles to Augment Anti-Tumor Immune Responses
Hargadon, K. M. (2013) · Journal of Cosmetics Dermatological Sciences and Applications · doi:10.4236/jcdsa.2013.32a002 · Cited by 2
“Adoptive transfer of cblb gene-silenced T cells into mice bearing B16 melanoma delayed tumor outgrowth and enhanced survival, and these results correlated with enhanced effector activity of CD8 TIL [172].”
BackgroundBogdanov, A. A., Vysochinskaya, V. V., Kornev, A. A., Emelyanov, A., Bogdanov, A. A., & Moiseyenko, V. M. (2021) · Practical oncology · doi:10.31917/2203204 · Cited by 2
Genome Editing for Engineering the Next Generation of Advanced Immune Cell Therapies
de Lima, S. C. G., Fantacini, D. M. C., Furtado, I. P., Rossetti, R., Silveira, R. M., Covas, D. T., & de Souza, L. E. B. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-33325-5_6 · Cited by 2
Ubiquitination and Deubiquitination in Melanoma Research and Clinically Relevant Outcomes
Guo, J., & Zhang, J. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.94512 · Cited by 2
Ubiquitin - Proteasome Pathway
Zhan, X. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.87547 · Cited by 2
Tang, J., & Zhang, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-67199-4_101569 · Cited by 1
Combining the strengths of cytotoxic T cells and nanomedicines for cancer immunotherapy
Wayteck, L. (2016) · Ghent University Academic Bibliography (Ghent University)
Goetz, B. T. (2016) · DigitalCommons@UNMC
Defective Immune Regulation in Multiple Sclerosis: E3 Ubiquitin Ligase Cbl-b and TLR Tolerance
Fujiwara, M. (2017) · OpenCommons - UConn (University of Connecticut)
Grassmann, S. A. (2018) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.22518
Shin, J. (2018) · University of Minnesota Digital Conservancy (University of Minnesota)
Tang, J., & Zhang, J. (2016) · Springer eBooks · doi:10.1007/978-1-4614-6438-9_101569-1
Polymersome-mediated Cbl-b silencing activates T cells against solid tumors
Cui, G., Shao, Y., Wang, J., Xu, C., Zhang, J., & Zhong, Z. (2025) · Biomaterials Science · doi:10.1039/d5bm00001g
Hoeck, J. V. (2021) · Ghent University Academic Bibliography (Ghent University)
Wang, P., & Li, Y. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01994-4
Metadata
- Authors
- Hinterleitner, R., Gruber, T., Pfeifhofer-Obermair, C., Lutz-Nicoladoni, C., Tzankov, A., Schuster, M., Penninger, J. M., Loibner, H., Lametschwandtner, G., Wolf, D., & Baier, G.
- Affiliations
- Innsbruck Medical University (AT)
- Apeiron Biologics (Austria) (AT)
- Institute of Molecular Biotechnology (AT)
- University of Bonn (DE)
- Corresponding author
- Baier, Gottfried
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-09-04
- Volume
- 7
- Issue
- 9
- Pages
- e44295
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3433477
- OpenAlex
- W2009329366
- Cited by
- 59
- References
- 39
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 4 · 2021: 3 · 2020: 8 · 2019: 4 · 2018: 4 · 2017: 11 · 2016: 3 · 2015: 4 · 2014: 2 · 2013: 7
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Austrian Federal Ministry of Economy, Family and Youth
- Austrian Science Fund (SFB021, P 22207)
- Bundesministerium für Verkehr, Innovation und Technologie
- Standortagentur Tirol
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- Cbl-b, siRNA knockdown, CD8+ T cells, adoptive cell transfer, dendritic cell vaccine, B16 melanoma, cancer immunotherapy, T cell activation threshold, ubiquitin ligase, ex vivo T cell engineering, tumor-infiltrating T cells, cytokine response, autoimmunity
- MeSH terms
- Animals, Dendritic Cells, Female, Humans, Melanoma, Experimental, Mice, Inbred C57BL, Skin Neoplasms, Transforming Growth Factor beta, CD8-Positive T-Lymphocytes, Adoptive Transfer, Cancer Vaccines, Gene Silencing, RNA, Small Interfering, Adaptor Proteins, Signal Transducing, Proto-Oncogene Proteins c-cbl, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.